Last reviewed · How we verify
CyclASol topical ocular, eye drops
CyclASol is a cyclosporine A formulation in a novel aqueous nanomicellar vehicle designed to enhance corneal penetration and treat dry eye disease by suppressing ocular surface inflammation.
CyclASol is a cyclosporine A formulation in a novel aqueous nanomicellar vehicle designed to enhance corneal penetration and treat dry eye disease by suppressing ocular surface inflammation. Used for Dry eye disease (keratoconjunctivitis sicca).
At a glance
| Generic name | CyclASol topical ocular, eye drops |
|---|---|
| Also known as | Ciclosporine (CsA), Ciclosporine (CSA) |
| Sponsor | Novaliq GmbH |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Cyclosporine A is a calcineurin inhibitor that reduces T-cell activation and pro-inflammatory cytokine production on the ocular surface. The CyclASol formulation uses a proprietary solubilization technology (Novaliq's VISIOMER platform) to deliver cyclosporine in an aqueous, preservative-free eye drop without requiring oil-based vehicles, improving tolerability and corneal bioavailability.
Approved indications
- Dry eye disease (keratoconjunctivitis sicca)
Common side effects
- Ocular irritation/burning
- Conjunctival hyperemia
- Blurred vision
Key clinical trials
- CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004 (PHASE3)
- ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (PHASE3)
- CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (PHASE2, PHASE3)
- CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CyclASol topical ocular, eye drops CI brief — competitive landscape report
- CyclASol topical ocular, eye drops updates RSS · CI watch RSS
- Novaliq GmbH portfolio CI